BRIEF-Roche Collaborates With Merck To Develop Companion Diagnostic Test To Identify Patients Eligible For Anti-Pd-1 Therapy [Reuters]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Reuters
BRIEF-Roche Collaborates With Merck To Develop Companion Diagnostic Test To Identify Patients Eligible For Anti-Pd-1 Therapy | Reuters 1 Min Read Dec 11 (Reuters) - Roche Holding AG: * ROCHE TO DEVELOP COMPANION DIAGNOSTIC TEST TO HELP IDENTIFY PATIENTS ELIGIBLE FOR ANTI-PD-1 THERAPY BASED ON BIOMARKER EXPRESSION, NOT LOCATION, OF SOLID TUMORS * ROCHE HOLDING AG - WILL SEEK FDA APPROVAL FOR BIOMARKER PANEL EXPECTED TO PROVIDE A STANDARDIZED PREDICTIVE TESTING OPTION FOR DMMR * ROCHE HOLDING AG - ENTERED COLLABORATION WITH MERCK TO DEVELOP A COMPANION DIAGNOSTIC TEST TO IDENTIFY PATIENTS ELIGIBLE FOR ANTI-PD-1 THERAPY * ROCHE HOLDING AG - COMPANIES WILL COLLABORATE ON DEVELOPMENT OF A PAN-CANCER COMPANION DIAGNOSTIC Source text for Eikon: Further company coverage: All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. © 2018 Reuters. All Rights Reserved. BRIEF-Roche Collaborates With Merck To Develop Companion Diagnostic Test To Ident
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- FDA approves Roche's Alecensa for early stage ALK+ lung cancer [Seeking Alpha]Seeking Alpha
- FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer [Yahoo! Finance]Yahoo! Finance
- FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung CancerBusiness Wire
- Roche's subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS [Yahoo! Finance]Yahoo! Finance
- Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MSBusiness Wire